OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
March 01, 2023
CHMP recommended the approval of AbbVie’s RINVOQ (upadacitinib) as a treatment for adults with moderate-to-severe Crohn’s disease.
February 27, 2023
Orchard Therapeutics has announced an agreement which will enable reimbursed access to Libmeldy for all eligible MLD patients in Sweden.
February 08, 2023
Roche’s Phase III global program, centered around the biologic crovalimab as a treatment for paroxysmal nocturnal haemoglobinuria, showed the drug was non-inferior to current standards of care.
February 07, 2023
iotaSciences isoPick is designed to expand handling solutions for cell biology and gene therapy applications.
February 02, 2023
The European bio/pharma industry’s high regulatory standards and GMP requirements are set to position the region as a frontrunner for pharmaceutical‑grade manufacturing of cannabis-based medicines.
Although some headway is being made into more gender-diverse executive levels in pharma, much more work is still needed.
January 20, 2023
CRB’s latest industry report includes an expanded audience to include many European countries, which has provided some interesting insights.
January 11, 2023
Chiesi will acquire Amryt Pharma, a commercial-stage biopharmaceutical company, in a deal worth up to $1.47 billion.
The company was awarded the Terra Carta Seal in recognition of its commitment to creating a sustainable future.
Ipsen’s $952 million acquisition of Albireo is designed to bolster the company's rare disease portfolio.